In a model of non-small cell lung adenocarcinoma, ABBV-085 (anti-LRRC15; a monomethyl auristatin E containing antibody-drug conjugate against LRRC15) treatment in combination with gemcitabine showed enhanced anti-tumorigenic efficacy in solid tumours compared with single-agent therapies, suggesting that it enhanced the delivery and/or efficacy of chemotherapy [102]. The gene discussed is LRRC15; the disease is non-small cell lung adenocarcinoma.